Sarepta Therapeutics reported Q3 2026 financial results with net product revenues of $323.8 million, driven by its PMO franchise and ELEVIDYS. The company achieved positive cash flow and non-GAAP operating income of $22.9 million while preparing for Phase 3 development in its DM1 and FSHD programs.
Term
Q3 2026
“After my first 90 days at Sarepta, I believe the fundamental strengths that attracted me to the company remain firmly intact: a durable Duchenne franchise, a promising pipeline with the potential to deliver differentiated medicines, and the financial strength to invest in our highest-value opportunities.”
Michael Severino, M.D., chief executive officer, Sarepta
“This quarter, we saw continued strength in our commercial execution. Our upcoming DM1 and FSHD datasets are important opportunities to demonstrate the depth of knockdown and downstream biological effects we believe our platform can achieve.”
Michael Severino, M.D., chief executive officer, Sarepta
Sarepta Therapeutics reported a net income of $297.6 million for the first nine months of 2026, a significant turnaround from a $301.2 million loss in the prior year period. Total revenues for the nine months reached $1.51 billion, driven by $983.0 million in net product sales and $530.4 million from collaboration and other revenue.
Sarepta Therapeutics entered into a settlement agreement with REGENXBIO, the University of Pennsylvania, and Catalent to resolve pending patent infringement litigation regarding the '274 and '617 patents. Sarepta will pay a lump sum of $39.0 million to REGENXBIO in exchange for a release of claims and a covenant not to sue regarding Sarepta's gene therapy products using the AAVrh74-based capsid, including ELEVIDYS. The settlement resolves all pending litigations with prejudice and includes no admission of liability.